F-star lines up Take­da pact weeks af­ter M&A ex­it; En route to Eu­rope de­ci­sion, Gen­Sight touts 5-year da­ta

Weeks af­ter wrap­ping up a month­s­long search for a new own­er, F-star Ther­a­peu­tics has signed a li­cens­ing agree­ment with Take­da for a new im­muno-on­col­o­gy bis­pe­cif­ic an­ti­body.

The deal terms are far from the big fig­ures float­ed by oth­er Big Phar­ma-biotech tie-ups in re­cent months, with Take­da dol­ing out $1 mil­lion to start and of­fer­ing up to $40 mil­lion more in back-end pay­ments if all mile­stones are met, the com­pa­nies said Wednes­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.